Navigation Links
Agent slows aging in mice

emale mice because of their hormonal status have other pathways to death and disability, or need higher or lower levels of NDGA to see an effect.”

The large, carefully controlled study at three sites, called the NIA Interventions Testing Program, is intended to provide some of the first reliable data on potential drugs to slow aging and its accompanying ills.

Miller says prior studies typically have been too small and their results hard to confirm in subsequent studies. “The National Institute on Aging decided to fund grants at three institutions to do studies of this sort in the right way,” he says.

In six to 10 months, once all the mice in the control group have died, the scientists will get answers to the really burning question: Will the mice fed NDGA, already well past middle age, live past the normal outer limit of old age" The longest that mice of this type usually live is around 1,000 to 1,100 days.

“If NDGA turns out to extend maximal lifespan by 20 or 30 percent, people would accept that as an important finding,” Miller says.

No one excited by these early results in mice is advised to bulk up on creosote bush leaves as a way to defy old age. If NDGA pushes the aging envelope in the final results of this study, other labs will likely try to repeat the results in animals. Much more research is needed before any possible human anti-aging drug could emerge, Miller says.

“Even if this agent turns out to be good for mice, it won’t be possible to tell without careful studies of humans whether NDGA is beneficial, useless, or harmful to people. Occasionally, something that is harmless in mice turns out to be highly toxic for people,” Miller cautions, adding that the Food and Drug Administration doesn’t evaluate the safety of such herbal remedies.
'"/>

Source:University of Michigan Health System


Page: 1 2

Related biology news :

1. Cancer drug slows poxvirus in mice
2. Stress substantially slows human bodys ability to heal
3. Cell therapy slows progression of an inherited neurological disease; Improves motor skills in mice
4. Diabetes slows nerve recovery after heart transplant
5. Protein found that slows hepatitis C growth in liver cells
6. Imaging Lymph Nodes with Nanoparticles
7. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
8. Special Imaging Study Shows Failing Hearts Are Energy Starved
9. How the environment could be damaging mens reproductive health
10. Human Cells Filmed Instantly Messaging for First Time
11. Duke engineers develop new 3-D cardiac imaging probe
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Agent slows aging mice

(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... HOUSTON, Oct. 22, 2010 Researchers can spend entire ... efforts featured in the pages of Science , ... won,t be the case, though, for two junior faculty ... Jacinta Conrad and Jeff Rimer, both assistant ...
... LA Research conducted by scientists at LSU Health Sciences ... brain act as valves to turn the hormone that regulates ... may lead to advances in treatment for diseases like high ... The research is published in the November 1, 2010 issue ...
... received two grants from the California Institutefor Regenerative Medicine ... treating neurological diseases and liver failure. The goal of ... toward the development of potential therapies within the next ... successful, they could then be further prepared as potential ...
Cached Biology News:UH engineering professors featured in consecutive issues of Science 2UH engineering professors featured in consecutive issues of Science 3LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension 2UCSF stem-cell based-neurological, liver therapy strategies advanced 2UCSF stem-cell based-neurological, liver therapy strategies advanced 3UCSF stem-cell based-neurological, liver therapy strategies advanced 4
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet ... a second US laboratory is to open in Manhattan, Kansas in early October, ... and long-term growth of research and development through collaboration with researchers from Kansas ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global ... and manufacture of highly valued cardiac markers used in early detection of heart ... protein chemistry has led to the development and commercialization of important cardiac biomarkers ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation (NYSE: ... today the closing of its previously announced public offering ... the underwriters of their option to purchase an additional ... price of $41.00 per share.  The exercise of the ... common stock sold by Intrexon to 5,609,756 shares and ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2
... constant currency revenue growth of 12.9 percent,- Full year ... and improving profitability reflects success of strategic ... for fiscal year 2009, BATESVILLE, Ind., Nov. 10 ... financial results for its fiscal,fourth quarter ended September 30, ...
... Incorporated,(Nasdaq: SPEX ) reported that the Nasdaq Stock ... its common stock from the Nasdaq,Global Market to the ... trading on the Nasdaq Capital Market on November 11, ... three market tier designations for,Nasdaq-listed stocks, and presently includes ...
... Conference Call Today at 4:30 p.m. Eastern Time -, ... MDVN ) today reported on its corporate progress and ... "The third quarter represented another quarter of significant,achievement and ... partnering,agreement with Pfizer for Dimebon. This collaboration not only ...
Cached Biology Technology:Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19Spherix Transfers Stock Listing to Nasdaq Capital Market 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8
... StabilZyme AP Conjugate Stabilizer is ... purified bovine protein and other non-toxic ... (4-Morpholine-ethanesulfonic acid), pH 5.5 6.5. ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ...
... When nonspecific binding is a ... a variety of immobilized NeutrAvidin products ... streptavidin. NeutrAvidin is a modified avidin ... to provide a biotin-binding protein with ...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
... generated hybridomas against a large variety ... you are provided with personalized project ... lines developed by Covance remain exclusive ... hybridoma development project has four phases: ...
Biology Products: